RxDoctor Payments Data

Theodore Ruza, DO

Psychiatry · West Bloomfield, MINPI 1346392735

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $76,405 of the $99,674 with a category attached, or 76.7%. Acadia Pharmaceuticals Inc accounts for 99.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $30,612 and has fallen 65.9% since, to $10,448 in 2025. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$99,674in general payments, 2019–2025

Across 140 payments — averaging $711.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$99K
  • Teva Pharmaceuticals USA, Inc.$192
  • Alkermes, Inc.$190
  • Bioxcel Therapeutics, Inc.$110
  • Avanir Pharmaceuticals, Inc.$29
  • Lundbeck LLC$16

What the payments were for

  • Consulting fees$10,10010%
  • Speaking & faculty fees$76,40577%
  • Travel & lodging$8,6419%
  • Food & beverage$4,5275%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,674 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$202,749
Medicare patients
378
Services billed
2,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate36$198,639
Invega SustennaPaliperidone Palmitate30$79,407
Risperidone ErRisperidone Microspheres32$33,022
Chlorpromazine Hcl83$21,960
EliquisApixaban17$9,501
Escitalopram Oxalate628$8,512
Quetiapine Fumarate740$7,708
Risperidone448$7,518
Mirtazapine430$6,586
Memantine Hcl198$4,404
Trazodone Hcl340$3,563
Clozapine28$3,472
Paliperidone ErPaliperidone20$3,351
Donepezil Hcl272$3,032
Lurasidone Hcl27$2,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$99,136$198,63936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →